More about

Osimertinib

News
June 08, 2023
13 min listen
Save

Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of June 5, 2023

Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of June 5, 2023

In this edition, surgery confers higher 5-year survival rates than radiotherapy; first-line combination extends PFS in lung cancer subgroup; pembrolizumab improves outcomes in early-stage resectable lung cancer, and more.

News
June 05, 2023
3 min read
Save

Study shows feasibility, potential benefits of lung cancer screening for nonsmokers

Study shows feasibility, potential benefits of lung cancer screening for nonsmokers

CHICAGO — A study that assessed the feasibility of lung cancer screening for certain nonsmokers yielded a higher invasive adenocarcinoma detection rate than the National Lung Screening Trial, which assessed screening for smokers who met key risk criteria.

News
June 04, 2023
3 min read
Save

Osimertinib after surgery reduces risk for death by 51% in resected EGFR-mutant NSCLC

Osimertinib after surgery reduces risk for death by 51% in resected <i>EGFR</i>-mutant NSCLC

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ADAURA trial presented at ASCO Annual Meeting.

News
June 02, 2023
2 min read
Save

Chemotherapy after first-line EGFR TKI fails to extend survival in advanced NSCLC

Chemotherapy after first-line EGFR TKI fails to extend survival in advanced NSCLC

CHICAGO — Platinum-doublet chemotherapy did not extend survival for patients with advanced nonsquamous non-small cell lung cancer who responded to EGFR tyrosine kinase inhibitor therapy, according to randomized phase 3 study results.

News
May 17, 2023
1 min read
Save

First-line combination extends PFS in lung cancer subgroup

First-line combination extends PFS in lung cancer subgroup

First-line osimertinib plus chemotherapy extended PFS compared with osimertinib alone for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, topline results of the randomized phase 3 FLAURA2 trial showed.

News
April 06, 2023
12 min listen
Save

Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of April 3, 2023

Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of April 3, 2023

In this edition, ‘paradigm shift’ in non-small cell lung cancer during past decade; osimertinib extends survival in early EGFR-mutated NSCLC; amivantamab shows durable activity in patients with advanced NSCLC, and more.

News
March 31, 2023
2 min read
Save

Osimertinib confers lasting DFS benefit in resected EGFR-mutant non-small cell lung cancer

Osimertinib confers lasting DFS benefit in resected <i>EGFR</i>-mutant non-small cell lung cancer

Osimertinib extended DFS and reduced risk for recurrence among patients with resected EGFR-mutated non-small cell lung cancer, according to an updated analysis of data from the phase 3 ADAURA trial published in Journal of Clinical Oncology.

News
March 09, 2023
1 min read
Save

Osimertinib extends survival in early EGFR-mutated non-small cell lung cancer

Osimertinib extends survival in early <i>EGFR</i>-mutated non-small cell lung cancer

Osimertinib conferred a statistically significant and clinically meaningful improvement in OS compared with placebo among patients with early-stage EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

News
February 28, 2023
1 min read
Save

Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints

Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints

Two phase 3 trials evaluating pembrolizumab in combination with additional agents failed to meet their primary endpoints, according to the agent’s manufacturer.

News
February 09, 2023
11 min listen
Save

Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of February 6, 2023

Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of February 6, 2023

In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more.

View more